

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT ESTABLISHMENT OF ZHEJIANG NUCLIDE THERAPY SPECIALTY ALLIANCE

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company, as a council member, together with a number of hospitals in Zhejiang Province jointly established “Zhejiang Nuclide Therapy Specialty Alliance” on 10 June 2023.

The Company, which has dedicated itself to the field of nuclear medical treatment for 40 years, has comprehensive arrangements in eight business areas such as radiopharmaceuticals, nuclear medical equipment, intelligent nuclear medicine and radioactive sources, aiming to provide users with a full range of products and solutions. The Company actively implemented the strategy of “Healthy China”, effectively promoted the development of the nuclear technology application industry in Zhejiang Province and specially set up the Nuclear Medicine Development Center, so as to facilitate the development of “One County, One Department” nuclear medicine program, make every effort to create the Overall Intelligent Nuclear Medicine Solutions and promote the high-quality development of intelligent nuclear medicine nationwide.

Zhejiang Province, as a leading province with respect to the economic development in China, took the lead in establishing the Nuclide Therapy Specialty Alliance at the right time. As a council member of the Alliance, the Company will make positive efforts to build the platform and provide service support, helping the Alliance to promote the construction of nuclear medicine across the province with a focus on nuclide therapy. Through expert support, expert consultation, seminar trainings and other ways, more nuclide therapy demonstration bases will be built. Meanwhile, the Company will facilitate the formulation of clinical guidelines and construction standards for nuclide therapy and gradually promote the development of intelligent nuclear medicine, so as to stimulate the standardized and high-quality development of nuclide therapy within the whole province. It is expected to develop Zhejiang Province into a major province for nuclide therapy with a demonstrative effect in China, through jointly building a platform and integrating resources by the Specialty Alliance, thus facilitating the construction of “Healthy China”.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 12 June 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Dai Shuquan, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Hui Wan Fai, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.